The estimated Net Worth of Mark A Emalfarb is at least $6.57 Million dollars as of 21 December 2021. Mr. Emalfarb owns over 150,000 units of Dyadic International stock worth over $5,492,519 and over the last 6 years he sold DYAI stock worth over $0. In addition, he makes $1,074,050 as President, Chief Executive Officer, and Director at Dyadic International.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Emalfarb DYAI stock SEC Form 4 insiders trading
Mark has made over 4 trades of the Dyadic International stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of DYAI stock worth $244,500 on 21 December 2021.
The largest trade he's ever made was exercising 400,000 units of Dyadic International stock on 2 June 2021 worth over $668,000. On average, Mark trades about 70,000 units every 98 days since 2019. As of 21 December 2021 he still owns at least 4,394,015 units of Dyadic International stock.
You can see the complete history of Mr. Emalfarb stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Emalfarb biography
Mark A. Emalfarb serves as President, Chief Executive Officer, Director of the Company. Mark A. Emalfarb is the founder of Dyadic, and currently serves as the President, Chief Executive Officer and a member of the Board of Directors of the Company. He has been a member of Dyadic’s Board and has previously served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015. Since founding the predecessor to Dyadic in 1979, Mr. Emalfarb has served as a Director, President and Chief Executive Officer for substantially all of that time and has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic’s patented and proprietary C1 fungal microorganism. Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the patented and proprietary C1 fungus and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners. Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.
What is the salary of Mark Emalfarb?
As the President, Chief Executive Officer, and Director of Dyadic International, the total compensation of Mark Emalfarb at Dyadic International is $1,074,050. There are no executives at Dyadic International getting paid more.
How old is Mark Emalfarb?
Mark Emalfarb is 64, he's been the President, Chief Executive Officer, and Director of Dyadic International since 2015. There are 5 older and 6 younger executives at Dyadic International. The oldest executive at Dyadic International, Inc. is Jack Kaye, 76, who is the Independent Director.
What's Mark Emalfarb's mailing address?
Mark's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL, INC., 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Insiders trading at Dyadic International
Over the last 6 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet, and Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
What does Dyadic International do?
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
What does Dyadic International's logo look like?
Complete history of Mr. Emalfarb stock trades at Dyadic International
Dyadic International executives and stock owners
Dyadic International executives and other stock owners filed with the SEC include:
-
Mark Emalfarb,
President, Chief Executive Officer, Director -
Mark A. Emalfarb,
Founder, CEO, Pres & Director -
Matthew Jones,
Managing Director - Business Development and Licensing -
Ping Rawson,
Chief Financial Officer, Chief Accounting Officer -
Matthew S. Jones,
Managing Director of Bus. Devel. & Licensing -
Ronen Tchelet,
Vice President of Research and Business Development -
Dr. Ronen Tchelet Ph.D.,
VP of Research & Bus. Devel. -
Jack Kaye,
Independent Director -
Arindam Bose,
Independent Director -
Michael Tarnok,
Independent Chairman of the Board -
Seth Herbst,
Independent Director -
Barry Buckland,
Independent Director -
Ana Gómez Rodriguez,
Sec. of the Board -
Joseph P. Hazelton,
Chief Bus. Officer -
Patrick K. Lucy,
Director -
Trust Under Agreement Dated...,
10% owner -
Joseph P Hazelton,
Chief Business Officer